Vital Therapies Inc  

(Public, NASDAQ:VTL)   Watch this stock  
Find more results for vital
24.51
+0.03 (0.12%)
May 4 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 23.95 - 25.14
52 week 10.66 - 35.20
Open 23.95
Vol / Avg. 67,675.00/76,464.00
Mkt cap 587.36M
P/E     -
Div/yield     -
EPS -2.74
Shares 23.99M
Beta     -
Inst. own 19%
May 12, 2015
Q1 2015 Vital Therapies Inc Earnings Call - 4:30PM EDT - Add to calendar
May 12, 2015
Q1 2015 Vital Therapies Inc Earnings Release - 4:00PM EDT - Add to calendar
Mar 19, 2015
Q4 2014 Vital Therapies Inc Earnings Call - Webcast
Mar 19, 2015
Q4 2014 Vital Therapies Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -57.73% -61.64%
Return on average equity -64.11% -214.80%
Employees 96 -
CDP Score - -

Address

15222 Avenue of Science Ste B
SAN DIEGO, CA 92128-3422
United States - Map
+1-858-6736840 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Vital Therapies, Inc. is a biotherapeutic company focused on developing a cell-based therapy targeting the treatment of all forms of acute liver failure. The Company�s product candidate, the ELAD� System, is a human cell-based, bio-artificial liver support system that operates outside the body, or extracorporeally, and is designed with the proposed intent to allow the patient�s own liver to regenerate to a healthy state, or to stabilize the patient until liver transplant. The ELAD System incorporates the human liver-derived cells, or VTL C3A cells, contained in four hollow fiber cartridges that are combined with single use customized disposable sets and an ancillary delivery system.

Officers and directors

Terence E. Winters Ph.D. Co-Chairman of the Board, Chief Executive Officer
Age: 72
Bio & Compensation  - Reuters
Muneer A. Satter J.D., M.B.A. Co-Chairman of the Board, Lead Director
Age: 54
Bio & Compensation  - Reuters
Michael V. Swanson M.B.A. Chief Financial Officer
Age: 55
Bio & Compensation  - Reuters
Robert A. Ashley Executive Vice President, Chief Technical Officer
Age: 57
Bio & Compensation  - Reuters
Duane Nash M.D, J.D. Executive Vice President, Chief Business Officer
Age: 44
Bio & Compensation  - Reuters
Aron P. Stern M.B.A. Chief Administrative Officer
Age: 61
Bio & Compensation  - Reuters
Andrew Henry Vice President - Clinical Operations
Age: 50
Bio & Compensation  - Reuters
Andrea Loewen-Rodriguez Vice President - Regulatory Affairs and Quality Assurance
Age: 47
Bio & Compensation  - Reuters
Richard Murawski Vice President - Manufacturing
Age: 66
Bio & Compensation  - Reuters
John M. Dunn General Counsel, Secretary
Age: 63
Bio & Compensation  - Reuters